The lawsuit claims that three major healthcare companies were pushing up the price of insulin by 1,200 percent.

The Federal Trade Commission voted unanimously to release additional findings from its yearslong probe into CVS Caremark, ...

The Federal Trade Commission said three top pharmacy suppliers made profits of 7,700 percent on a lifesaving hypertension ...

Patient Capital Management, a value investing firm, released its “Patient Capital Opportunity Equity Strategy” fourth quarter ...

According to the American Diabetes Association, approximately 8.4 million people in the United States need insulin to survive ...

With a market cap of $64.8 billion, CVS Health Corporation (CVS) is a leading pharmacy innovation company providing a wide ...

Zydus Lifesciences announced that it has entered into an agreement with CVS Caremark, a CVS Health (CVS) company, to add Zituvio, Zituvimet and ...

Analysts have recently evaluated CVS Health and provided 12-month price targets. The average target is $68.07, accompanied by ...

CVS Health's poor 2024 performance was driven by ... PBMs and MA plans are core to the CVS Caremark and Aetna insurance segments. But will the rhetoric stick? PBMs are an easy target.

Allen Lutz, an analyst from Bank of America Securities, maintained the Buy rating on CVS Health (CVS – Research Report). The associated price ...

CVS Health Corporation is a vertically integrated healthcare corporation in the United States. The company owns a leading ...

Zydus Lifesciences announced that it has entered into an agreement with CVS Caremark, a CVS Health (CVS) company, to add Zituvio, Zituvimet and Zituvimet XR tablets to its template formulary.